• hiPSC-Derived Intestinal Organoids Advance Pharmacokinetics

  2026-08-06

  This study establishes a streamlined protocol for deriving intestinal organoids from human pluripotent stem cells, offering a physiologically relevant model for pharmacokinetic research. Its findings enable more predictive in vitro evaluation of drug absorption and metabolism compared to conventional models.

• ASK1 Inhibition by GS-4997 Attenuates Tubulointerstitial Inj

  2026-08-05

  This article examines the recent study demonstrating that GS-4997 (Selonsertib), a selective ASK1 inhibitor, effectively halts the progression of tubulointerstitial injury in lupus nephritis models. The findings elucidate the mechanism by which ASK1 inhibition interrupts downstream MAPK signaling, reducing renal inflammation and fibrosis, and highlight practical considerations for renal fibrosis research.

• 3-Bromopyruvate and Cetuximab Synergy Overcomes CRC Resistan

  2026-08-05

  This study demonstrates that combining 3-bromopyruvate with cetuximab effectively reverses drug resistance in colorectal cancer (CRC) cells by inducing autophagy-dependent ferroptosis and apoptosis. The mechanistic analysis highlights the central role of FOXO3a-mediated signaling, providing a potential therapeutic avenue for refractory metastatic CRC.

• Poria cocos Polysaccharides Mitigate ALD via NRF2/Ferroptosi

  2026-08-04

  This study demonstrates that Poria cocos polysaccharides (PCP) alleviate alcoholic liver disease (ALD) by modulating the NRF2 signaling pathway and reducing ferroptosis. The findings highlight a mechanistic link between NRF2 regulation, oxidative stress, and liver protection, suggesting new targets for ALD intervention.

• Sulfo-NHS-Biotin: Enabling Precision in Translational Proteo

  2026-08-04

  Explore how Sulfo-NHS-Biotin empowers translational researchers to map cell surface proteomes with mechanistic fidelity—unlocking new avenues for host-pathogen studies, therapeutic innovation, and reproducibility in advanced protein labeling workflows. This thought-leadership article bridges biochemical insight, protocol optimization, and the evolving landscape of host-directed therapies, with actionable guidance grounded in landmark evidence.

• RWJ 67657 in Inflammatory Disease Research: Protocols & Pitf

  2026-08-03

  RWJ 67657 (also known as JNJ-3026582) is a highly selective, orally active inhibitor of p38α/β MAP kinases, offering new experimental leverage for dissecting TNF-alpha-driven inflammation. Learn how its dual-action mechanism, workflow-specific optimizations, and troubleshooting strategies enable more precise interrogation of cytokine regulation and disease modeling.

• Capsaicin (SKU C6366): Reliable Solutions for Cell Assays

  2026-08-03

  This article delivers scenario-driven, evidence-based guidance for leveraging Capsaicin (SKU C6366) in cell viability, proliferation, and cytotoxicity workflows. By addressing real laboratory challenges and substantiating recommendations with quantitative data, we demonstrate how Capsaicin from APExBIO supports reproducibility and robust mechanistic interrogation in TRPV1 and KDM1A/LSD1 research.

• DOT1L Inhibition Primes Innate Immunity in Multiple Myeloma

  2026-08-02

  The referenced study demonstrates that DOT1L inhibition reprograms innate immune signaling in multiple myeloma, potentiating the response to immunomodulatory drugs such as lenalidomide. These results highlight DOT1L as a preferential epigenetic therapeutic target, providing mechanistic insights that may inform future combinatorial strategies in MM treatment.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Lab U

  2026-08-01

  This article provides evidence-based, scenario-driven guidance for selecting and optimizing the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO), SKU K1007, for cell viability, proliferation, and cytotoxicity assays. By addressing real-world laboratory challenges and integrating recent literature, we highlight how this APExBIO solution ensures reproducibility and compatibility in sensitive workflows.

• SB 431542 in Antitumor Immunity: TGF-β Pathway Insights & Pr

  2026-07-31

  Explore how SB 431542, a potent ALK5 inhibitor, advances immuno-oncology by modulating TGF-β signaling and Treg populations. This article offers unique, assay-ready insights and practical protocols, extending beyond standard applications.

• ABT-199 (Venetoclax): Redefining Apoptosis Targeting in Hema

  2026-07-31

  This thought-leadership article explores how the mechanistic selectivity of ABT-199 (Venetoclax) as a Bcl-2 inhibitor enables a new era of apoptosis research and translation in hematologic malignancies. Integrating recent mechanistic insights—including from studies on cell death pathways independent of transcription loss—we provide actionable guidance for translational teams, highlight protocol design, and compare the competitive landscape. This piece extends current discourse by synthesizing strategic, workflow, and mechanistic considerations, positioning ABT-199 as a pivotal tool for next-generation research.

• Bufalin-CRISPR Nanomedicine Enables Synergistic CRC Immunoth

  2026-07-30

  This study introduces a calcium lactate nanoparticle platform co-delivering bufalin and CRISPR/Cas9 RNP to induce pyroptosis/apoptosis and reprogram the tumor microenvironment in colorectal cancer. The findings demonstrate a potent, multimodal immunotherapy strategy capable of overcoming current treatment limitations.

• WY-14643 (Pirinixic Acid): Precision Tool for PPARα Research

  2026-07-30

  WY-14643 (Pirinixic Acid) is the gold standard for dissecting PPARα-driven lipid metabolism and inflammation in advanced metabolic disorder models. This guide delivers protocol-ready workflows, troubleshooting insights, and context from the latest omics-driven research—empowering reproducible, high-impact studies.

• SP2509: Lysine-Specific Demethylase 1 Antagonist for AML Res

  2026-07-29

  SP2509 stands out as a highly potent and selective Lysine-specific demethylase 1 antagonist, enabling precise epigenetic modulation in acute myeloid leukemia (AML) studies. Its robust apoptosis induction, differentiation-promoting effects, and compatibility with combinatorial epigenetic therapies position SP2509 as an indispensable tool for advanced cancer epigenetics workflows.

• miR-18a Drives Glioblastoma by Suppressing ALOXE3 and Ferrop

  2026-07-29

  This study identifies the miR-18a/ALOXE3 axis as a key driver of glioblastoma progression by impairing ferroptosis and promoting tumor cell migration. The findings highlight ALOXE3 downregulation as a mechanism of resistance to p53-SLC7A11-dependent cell death, suggesting new therapeutic avenues targeting lipid metabolism and ferroptosis regulation in aggressive brain tumors.

452 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page